Chronic inflammatory demyelinating polyneuropathy (CIDP): Change of serum IgG dimer levels during treatment with intravenous immunoglobulins

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Ritter, Christian ^a,b,c   Bobylev, Ilja ^a,b   Lehmann, Helmar C ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Autoantibody; Immune neuropathy; Inflammation; Surrogate marker

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; DIMER; GANGLIOSIDE GQ 1B ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; BIOLOGICAL MARKER; GANGLIOSIDE; GQ1B GANGLIOSIDE; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG RESPONSE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PERIPHERAL NERVE; BLOOD; DIMERIZATION; IMMUNOLOGY; MILLER FISHER SYNDROME; NERVE FIBER; PATHOLOGY; POLYRADICULONEUROPATHY;

AGED; BIOMARKERS; DIMERIZATION; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MILLER FISHER SYNDROME; MYASTHENIA GRAVIS; NERVE FIBERS; PERIPHERAL NERVES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84938926759     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0361-1     Document Type: Article

References (33)

1. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst. 2014;19:2-13.
2. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7:507-17.
3. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9:402-12.
4. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating neuropathy. N Engl J Med. 2005;352:1343-56.
5. Lehmann HC, Hughes RA, Hartung HP. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handb Clin Neurol. 2013;115:415-27.
6. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12, CD001797.
7. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-44.
8. Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci. 2013;34:445-57.
9. Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol. 2011;231:61-9.
10. Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuroimmunol. 2014;274:225-9.
11. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol. 2002;14:1303-11.
12. Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, et al. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2010;162:543-9.
13. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18:884-8.
14. Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994;7:537-48.
15. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995;8:405-13.
16. Schaub A, von Gunten S, Vogel M, Wymann S, Rüegsegger M, Stadler BM, et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy. 2011;66:1030-7.
17. Schaub A, Wymann S, Heller M, Ghielmetti M, Beleznay Z, Stadler BM, et al. Self-reactivity in the dimeric intravenous immunoglobulin fraction. Ann N Y Acad Sci. 2007;1110:681-93.
18. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38:150-7.
19. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095-9.
20. Morgan AC, Rossen RD, Twomey JJ. Naturally occurring circulating immune complexes: normal human serum contains idiotype-anti-idiotype complexes dissociable by certain IgG antiglobulins. J Immunol. 1979;122:1672-80.
21. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol. 1990;144:1387-95.
22. Joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst. 2010;15:1-9.
23. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195-201.
24. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev. 1994;139:159-72.
25. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988;25:41-8.
26. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, Tool AT, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 2000;95:1856-61.
27. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990;85:620-5.
28. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991;83:298-303.
29. Sanvito L, Makowska A, Mahdi-Rogers M, Hadden R, Peakman M, Gregson N, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009;80:333-8.
30. Melendez-Vasquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997;73:124-34.
31. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Suárez-Calvet X, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73:370-80.
32. Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012;79:2241-8.
33. Nobile-Orazio E, Giannotta C, Briani C. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol. 2010;219:119-22.